Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.91 |
---|---|
High | 0.95 |
Low | 0.886 |
Bid | 0.8904 |
Offer | 0.91 |
Previous close | 0.914 |
Average volume | 874.76k |
---|---|
Shares outstanding | 82.40m |
Free float | 81.09m |
P/E (TTM) | -- |
Market cap | 75.31m USD |
EPS (TTM) | -1.70 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
- Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
- Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
- Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
- Adicet Bio to Participate in Upcoming Investor Conferences
- Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
- Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
- Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
More ▼